Trial reportBlood advances2019
PD-L1 and tumor-associated macrophages in de novo DLBCL.
Trial report in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05280626 (First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP), which is not on this map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study
Who cites it
53 citing papers in PubMed, 80 citations in OpenAlex.
- PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.Blood advances · 2020Trial
- Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.Blood neoplasia · 2026Article
- Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?Diagnostics (Basel, Switzerland) · 2026Article
- Host heterogeneity shapes clonal selection and organotropism in an extranodal lymphoma mouse model.Cell death & disease · 2026Article
- Article
- Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse.Frontiers in molecular medicine · 2026Article
- CircRNA-mediated regulation of immune checkpoints in lymphoma: a multidimensional network perspective.Frontiers in immunology · 2026Review
- Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas.Haematologica · 2025Article
- Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma.Biomedicines · 2025Review
- PDL1-expressing macrophages infiltrate diffuse large B-cell lymphoma and promote lymphoma growth in a MYC-driven experimental model.Blood cancer journal · 2025Article
- Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive black phosphorus.Drug delivery and translational research · 2025Article
- Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Frontiers in immunology · 2025Review
- Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (NanoScience and technology of advanced materials · 2025Article
- Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis.Open life sciences · 2025Article
- Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients.International journal of molecular sciences · 2024Article
- PD-L1HemaSphere · 2024Article
- Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.International journal of molecular sciences · 2024Review
- The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.Radiology and oncology · 2024Article
- Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed death-ligand 1 (PD-L1) and its receptor, programmed cell death-1 (PD-1), are important negative regulators of immune cell activation. Therapeutically targeting PD-1/PD-L1 in diffuse large B-cell lymphoma (DLBCL) patients with a single agent has limited activity, meriting a deeper understanding of this complex biology and of available PD-L1 clinical assays. In this study, we leveraged 2 large de novo DLBCL phase 3 trials (GOYA and MAIN) to better understand the biologic and clinical relevance of PD-L1 in de novo DLBCL. PD-L1 was expressed on myeloid cells in 85% to 95% of DLBCL patients (depending on staining procedure), compared with 10% on tumor cells, and correlated with macrophage gene expression. PD-L1 did not identify high-risk patients in de novo DLBCL; it correlated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.